Stillwater Investment Management LLC increased its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 28,067 shares of the company’s stock after purchasing an additional 135 shares during the period. Johnson & Johnson accounts for 1.5% of Stillwater Investment Management LLC’s portfolio, making the stock its 12th biggest position. Stillwater Investment Management LLC’s holdings in Johnson & Johnson were worth $4,982,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in Johnson & Johnson by 1.4% in the first quarter. Vanguard Group Inc. now owns 238,141,110 shares of the company’s stock worth $42,205,749,000 after acquiring an additional 3,358,478 shares in the last quarter. BlackRock Inc. boosted its holdings in Johnson & Johnson by 0.4% in the first quarter. BlackRock Inc. now owns 200,799,189 shares of the company’s stock worth $35,587,638,000 after acquiring an additional 777,837 shares in the last quarter. State Street Corp boosted its holdings in Johnson & Johnson by 1.8% in the fourth quarter. State Street Corp now owns 144,677,639 shares of the company’s stock worth $24,750,004,000 after acquiring an additional 2,492,359 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 2.5% during the fourth quarter. Geode Capital Management LLC now owns 44,405,610 shares of the company’s stock valued at $7,576,867,000 after purchasing an additional 1,084,834 shares in the last quarter. Finally, Wellington Management Group LLP lifted its holdings in shares of Johnson & Johnson by 0.8% during the first quarter. Wellington Management Group LLP now owns 32,772,594 shares of the company’s stock valued at $5,808,286,000 after purchasing an additional 265,330 shares in the last quarter. 68.59% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson Stock Up 1.5 %
Johnson & Johnson stock opened at $167.60 on Friday. The stock has a market cap of $440.65 billion, a PE ratio of 24.40, a price-to-earnings-growth ratio of 2.94 and a beta of 0.61. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.17 and a current ratio of 1.42. Johnson & Johnson has a one year low of $155.72 and a one year high of $186.69. The stock has a fifty day moving average of $169.17 and a 200 day moving average of $174.20.
Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.57 by $0.02. The business had revenue of $24.02 billion during the quarter, compared to analysts’ expectations of $23.85 billion. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The business’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.48 earnings per share. As a group, sell-side analysts predict that Johnson & Johnson will post 10.7 EPS for the current year.
Johnson & Johnson Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd were given a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a yield of 2.70%. The ex-dividend date of this dividend was Monday, August 22nd. Johnson & Johnson’s payout ratio is 65.79%.
Johnson & Johnson announced that its Board of Directors has approved a share repurchase program on Wednesday, September 14th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the company to buy up to 1.2% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s leadership believes its stock is undervalued.
Wall Street Analyst Weigh In
A number of research analysts have recently issued reports on JNJ shares. SVB Leerink lowered their price target on Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. Daiwa Capital Markets started coverage on Johnson & Johnson in a report on Wednesday, June 22nd. They set an “outperform” rating on the stock. Morgan Stanley lowered their price target on Johnson & Johnson from $174.00 to $173.00 and set an “equal weight” rating on the stock in a report on Monday, September 12th. Citigroup lowered their price target on Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Finally, Wells Fargo & Company upped their price objective on Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a research report on Wednesday, July 13th. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $189.78.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.